Literature DB >> 31274694

Trends of antidementia drugs use in outpatients with Alzheimer's disease in six major cities of China: 2012-2017.

Lingyan Yu1, Xueying Chen1, Zhenwei Yu2.   

Abstract

Alzheimer's disease is a devastating neurodegenerative disease that requires pharmacological intervention. We conducted a descriptive study using pharmacy prescription data of antidementia drugs. Prescription information of 99 541 patients was obtained from 55 hospitals. Overall the number of Alzheimer's disease outpatients of sampling days increased from 10 239 in 2012 to 20 546 in 2017. The main age range of patients suffering Alzheimer's disease was 75-84, while the patients aged above 85 was increasing. Nonusers of antidementia drugs, cholinesterase inhibitors (ChEIs) and memantine slowly decreased over the study period. The percentage of patients taking ChEIs and ChEIs-combined memantine increased. The most frequently prescribed ChEI was donepezil. These results are mostly in line with the guideline recommendations and clinical evidence during the study period. Efforts should be made to reduce the number of nonusers and optimize the use of antidementia drugs.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31274694     DOI: 10.1097/YIC.0000000000000278

Source DB:  PubMed          Journal:  Int Clin Psychopharmacol        ISSN: 0268-1315            Impact factor:   1.659


  3 in total

1.  Prescribing trends of glaucoma drugs in six major cities of China from 2013 to 2017.

Authors:  Lingyan Yu; Kai Ding; Lifang Luo; Zhenwei Yu
Journal:  PLoS One       Date:  2020-01-13       Impact factor: 3.240

2.  Anti-seizure Medication Prescription in Adult Outpatients With Epilepsy in China, 2013-2018.

Authors:  Lingyan Yu; Wenjie Zhu; Xiuping Zhu; Yan Lu; Zhenwei Yu; Haibin Dai
Journal:  Front Neurol       Date:  2021-05-24       Impact factor: 4.003

3.  Utilization of Drugs for Attention-Deficit Hyperactivity Disorder Among Young Patients in China, 2010-2019.

Authors:  Zhiliang Wang; Xiaoyan Wu; Zhenwei Yu; Lingyan Yu
Journal:  Front Psychiatry       Date:  2022-02-09       Impact factor: 4.157

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.